Conditions: Bladder Cancer Bladder (Urothelial, Transitional Cell) Cancer Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 43
Healthy volunteers: no

Brief summary:
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.

Detailed description:
Based on the results from the Phase 1 study of pazopanib combined with paclitaxel and the activity of paclitaxel in urothelial cancer, testing this regimen in a disease where there is an unmet need appears appropriate.

Arms:
arm 1: Cycle of 28 days. Pazopanib: 800mg daily

Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15

Interventions: intervention 1: Pazopanib (GW786034) intervention 2: Paclitaxel
Intervention descriptions: intervention 1: Cycle of 28 days. Pazopanib: 800mg/day intervention 2: Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15

Protocol document: